2022
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Internal Medicine 2022, 182: 179-184. PMID: 34846533, PMCID: PMC8634151, DOI: 10.1001/jamainternmed.2021.7382.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Maccabi Healthcare ServicesBooster doseBNT162b2 vaccineMRNA vaccinesPositive SARS-CoV-2 polymerase chain reaction testSARS-CoV-2 polymerase chain reaction testPreliminary retrospective case–control studyRetrospective case-control studyPositive PCR test resultsBNT162b2 mRNA vaccineVaccine-derived protectionTest-negative designDuration of immunityCase-control studyPolymerase chain reaction testEstimated odds ratioHealthcare servicesCase-control analysisPCR test resultsPositive test resultsChain reaction testCase-control designTesting PositiveOdds ratio
2021
Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform
Nagar R, Ambiya M, Dalal S, Bhadauriya P, Abdullah H, Shahnawaz M, Weinberger D. Real-time monitoring of the rollout of pneumococcal conjugate vaccines in rural India using a digital tracking platform. Gates Open Research 2021, 5: 16. DOI: 10.12688/gatesopenres.13206.1.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineBooster doseConjugate vaccineImmunization programsRoutine immunization programPercent of childrenMonths of ageFirst doseThird doseVaccination statusPrimary dosesSecond dosePneumococcal transmissionVaccine programDigital health platformPCV13Vaccine deliveryOnly dosesDoseMaximal benefitVaccineTime pointsRural IndiaDosesHealth platform